{"id":60656,"date":"2024-02-28T07:01:04","date_gmt":"2024-02-28T07:01:04","guid":{"rendered":"https:\/\/medsname.com\/valprol-cr\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"valprol-cr","status":"publish","type":"product","link":"https:\/\/medsbase.com\/el\/valprol-cr\/","title":{"rendered":"Valprol-CR"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">&#9889; Quick Answer &mdash; What is Valprol-CR?<\/h3>\n<p style=\"margin:0;\"><strong>Valprol-CR<\/strong> \u03b5\u03af\u03bd\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03bf\u03c5 \u03c3\u03c4\u03cc\u03bc\u03b1\u03c4\u03bf\u03c2 <strong>controlled-release tablet<\/strong> from Intas Pharmaceuticals containing <strong>sodium valproate + valproic acid<\/strong> &mdash; a broad-spectrum anti-epileptic, mood stabiliser and migraine-prophylaxis drug. Available in <strong>200 mg and 750 mg<\/strong> CR strengths. Used for: <strong>multiple seizure types in epilepsy<\/strong> (generalised tonic-clonic, absence, myoclonic, partial), <strong>acute mania in bipolar I disorder<\/strong>, \u03ba\u03b1\u03b9 <strong>. \u03a5\u03c0\u03ac\u03c1\u03c7\u03bf\u03c5\u03bd \u03b5\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2 \u03b5\u03ba\u03c4\u03cc\u03c2 \u03b5\u03c4\u03b9\u03ba\u03ad\u03c4\u03b1\u03c2 \u03b3\u03b9\u03b1 \u03c7\u03c1\u03ae\u03c3\u03b7 \u03c3\u03b5<\/strong>. Adult dosing: 600&ndash;2,500 mg\/day in divided doses. Take with or after food to reduce GI upset. <strong>FDA Pregnancy Category X for migraine, Category D for epilepsy<\/strong> &mdash; one of the most teratogenic drugs in routine clinical use. Women of childbearing potential need explicit pregnancy-prevention counselling and should usually avoid valproate unless other options have failed. Mandatory monitoring: <strong>baseline + periodic LFTs, FBC, ammonia level if symptomatic<\/strong>. Never stop abruptly &mdash; abrupt discontinuation can precipitate status epilepticus.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>\u0391\u03c5\u03c4\u03cc \u03c0\u03bf\u03c5 \u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03b5\u03c4\u03b5 \u03bc\u03b5 \u03c4\u03b7\u03bd MedsBase:<\/strong> \u03a0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03bf\u03c2 \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ae\u03c2 WHO-GMP \u00b7 \u0394\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u00b7 \u03a0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae \u00b7 1,400+ \u03b5\u03c0\u03b1\u03bb\u03b7\u03b8\u03b5\u03c5\u03bc\u03ad\u03bd\u03b5\u03c2 <a href=\"https:\/\/medsbase.com\/el\/reviews\/\">\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ad\u03c2 \u03c0\u03b5\u03bb\u03b1\u03c4\u03ce\u03bd<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd <a href=\"https:\/\/medsbase.com\/el\/medsbase-re-shipment-assurance-policy\/\"><strong>\u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/strong><\/a> \u2014 \u03b5\u03ac\u03bd \u03c4\u03bf \u03b4\u03ad\u03bc\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd, \u03c4\u03bf \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5.<\/p>\n<h3>\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n<p>\u03a4\u03b1 \u03b3\u03b5\u03bd\u03cc\u03c3\u03b7\u03bc\u03b1 \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03ac \u03bc\u03b1\u03c2 \u03c0\u03c1\u03bf\u03ad\u03c1\u03c7\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ad\u03c2 \u03c0\u03bf\u03c5 \u03c0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd WHO-GMP \u03ba\u03b1\u03b9 \u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03bd\u03c4\u03b1\u03b9 \u03c0\u03b1\u03b3\u03ba\u03bf\u03c3\u03bc\u03af\u03c9\u03c2 \u03c3\u03b5 \u03b4\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae, \u03b1\u03c0\u03bb\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u2014 \u03c7\u03c9\u03c1\u03af\u03c2 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5 \u03c3\u03c4\u03bf \u03b5\u03be\u03c9\u03c4\u03b5\u03c1\u03b9\u03ba\u03cc \u03c4\u03bf\u03c5 \u03b4\u03ad\u03bc\u03b1\u03c4\u03bf\u03c2. \u039f\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u03b4\u03c1\u03bf\u03bc\u03bf\u03bb\u03bf\u03b3\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03bc\u03ad\u03c3\u03c9 \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf\u03c5 \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae (\u03bf\u03b9 \u03c0\u03b5\u03c1\u03b9\u03b3\u03c1\u03b1\u03c6\u03ad\u03c2 \u03b5\u03ba\u03ba\u03b1\u03b8\u03ac\u03c1\u03b9\u03c3\u03b7\u03c2 \u03c0\u03b5\u03c1\u03b9\u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03bf\u03c5\u03bd \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ce\u03bd \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u2014 \u03c0\u03bf\u03c4\u03ad \u201cMedsBase\u201d \u03ae \u03bf\u03c0\u03bf\u03b9\u03bf\u03b4\u03ae\u03c0\u03bf\u03c4\u03b5 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5). \u0393\u03af\u03bd\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b4\u03b5\u03ba\u03c4\u03ad\u03c2 \u03ba\u03b1\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03c1\u03c5\u03c0\u03c4\u03bf\u03bd\u03bf\u03bc\u03af\u03c3\u03bc\u03b1\u03c4\u03b1 \u03ba\u03b1\u03b9 \u03c4\u03c1\u03b1\u03c0\u03b5\u03b6\u03b9\u03ba\u03ae \u03bc\u03b5\u03c4\u03b1\u03c6\u03bf\u03c1\u03ac SEPA. \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2 \u0395\u03be\u03b1\u03c3\u03c6\u03b1\u03bb\u03af\u03c3\u03b5\u03ce\u03c2 \u03bc\u03b1\u03c2.<\/p>\n<h2 class=\"wp-block-heading\">What Is Valprol-CR?<\/h2>\n<p>Valprol-CR is an oral controlled-release tablet from Intas Pharmaceuticals containing <strong>sodium valproate<\/strong> in combination with <strong>valproic acid<\/strong> (the same active molecule, different salt form &mdash; in solution they are equivalent). The CR (controlled-release) formulation gradually releases the active over 12&ndash;24 hours, allowing once-daily or twice-daily dosing instead of the three-or-four-times-daily schedule needed with immediate-release valproate.<\/p>\n<p>Valproate is one of the oldest and most broad-spectrum anti-epileptic drugs in use. It is licensed for multiple seizure types in epilepsy, acute mania in bipolar I disorder, and migraine prophylaxis. The CR formulation is preferred for adults requiring sustained 24-hour drug levels &mdash; particularly those who experience peak-related side effects (drowsiness, tremor) on immediate-release valproate.<\/p>\n<h2 class=\"wp-block-heading\">How Does Valprol-CR Work?<\/h2>\n<p>Sodium valproate has multiple complementary mechanisms that together produce its broad-spectrum anti-seizure and mood-stabilising effects:<\/p>\n<ul>\n<li><strong>\u0391\u03c0\u03bf\u03ba\u03bb\u03b5\u03b9\u03c3\u03bc\u03cc\u03c2 \u03ba\u03b1\u03bd\u03b1\u03bb\u03b9\u03bf\u03cd \u03bd\u03b1\u03c4\u03c1\u03af\u03bf\u03c5 \u03b5\u03bb\u03b5\u03b3\u03c7\u03cc\u03bc\u03b5\u03bd\u03bf\u03c5 \u03b1\u03c0\u03cc \u03c4\u03ac\u03c3\u03b7<\/strong> &mdash; reduces high-frequency neuronal firing, the basis of its anti-seizure effect on partial and generalised tonic-clonic seizures.<\/li>\n<li><strong>T-type calcium channel inhibition<\/strong> &mdash; particularly relevant to absence seizures, where T-type calcium currents in thalamocortical neurons drive the spike-wave pattern.<\/li>\n<li><strong>GABAergic enhancement<\/strong> &mdash; raises brain GABA concentration through inhibition of GABA-degrading enzymes (GABA-T and succinic semialdehyde dehydrogenase) and increased GABA synthesis.<\/li>\n<li><strong>NMDA receptor modulation<\/strong> &mdash; reduces excitatory glutamate transmission.<\/li>\n<\/ul>\n<p>The combined effect is a wide therapeutic spectrum across seizure types, mood-stabilising activity in bipolar I disorder, and migraine prophylaxis through cortical-spreading-depression suppression.<\/p>\n<h2 class=\"wp-block-heading\">\u03a7\u03c1\u03ae\u03c3\u03b5\u03b9\u03c2 \u03ba\u03b1\u03b9 \u03b5\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2<\/h2>\n<ul>\n<li><strong>Epilepsy &mdash; generalised tonic-clonic seizures<\/strong> (first-line)<\/li>\n<li><strong>Epilepsy &mdash; absence seizures<\/strong> (first-line, especially in childhood and juvenile-onset)<\/li>\n<li><strong>Epilepsy &mdash; myoclonic seizures<\/strong> (first-line for juvenile myoclonic epilepsy)<\/li>\n<li><strong>Epilepsy &mdash; partial (focal) seizures<\/strong> (with or without secondary generalisation)<\/li>\n<li><strong>\u03c3\u03cd\u03bd\u03b4\u03c1\u03bf\u03bc\u03bf Lennox-Gastaut<\/strong> and other mixed seizure types<\/li>\n<li><strong>Bipolar I disorder &mdash; acute mania<\/strong> (FDA-approved monotherapy)<\/li>\n<li><strong>Bipolar I disorder &mdash; maintenance therapy<\/strong> (off-label, widely used)<\/li>\n<li><strong>\u03a0\u03c1\u03cc\u03bb\u03b7\u03c8\u03b7 \u03bc\u03b9\u03b3\u03ba\u03c1\u03b1\u03af\u03bd\u03b7\u03c2<\/strong> in adults (FDA-approved when migraines are frequent and disabling)<\/li>\n<li><strong>\u0395\u03ba\u03c4\u03cc\u03c2 \u03b5\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03c9\u03bd:<\/strong> behavioural agitation in dementia (no longer recommended &mdash; mortality signal), aggression and impulse control, neuropathic pain<\/li>\n<\/ul>\n<p>Valprol-CR is <strong>\u03b4\u03b5\u03bd<\/strong> first-line for: women of childbearing potential who could become pregnant (because of teratogenicity), pure absence seizures in young children if ethosuximide is available (cleaner safety), or generalised anxiety \/ unipolar depression. <strong>Behavioural agitation in dementia is no longer a recommended use<\/strong> &mdash; observational data suggest increased mortality, similar to the antipsychotic-in-dementia signal.<\/p>\n<h2 class=\"wp-block-heading\">Valprol-CR Dosage and How to Take<\/h2>\n<p>Valprol-CR comes at <strong>200 mg<\/strong> \u03ba\u03b1\u03b9 <strong>750 mg<\/strong> controlled-release strengths.<\/p>\n<p><strong>Standard adult dosing by indication:<\/strong><\/p>\n<ul>\n<li><strong>Epilepsy:<\/strong> Start 600 mg\/day (300 mg twice daily). Increase by 200 mg every 3 days based on seizure control. Maintenance 1,000&ndash;2,000 mg\/day in 1&ndash;2 divided doses. Maximum 2,500 mg\/day.<\/li>\n<li><strong>Bipolar I (acute mania):<\/strong> Start 750 mg\/day in divided doses; increase rapidly to achieve serum level 50&ndash;125 &micro;g\/mL. Maintenance 1,000&ndash;2,500 mg\/day.<\/li>\n<li><strong>\u03a0\u03c1\u03bf\u03c6\u03cd\u03bb\u03b1\u03be\u03b7 \u03b7\u03bc\u03b9\u03ba\u03c1\u03b1\u03bd\u03af\u03b1\u03c2:<\/strong> Start 250 mg twice daily; increase to 500&ndash;1,000 mg\/day if needed. Many patients respond at 500 mg\/day.<\/li>\n<\/ul>\n<h3 class=\"wp-block-heading\">How to Take Valprol-CR Properly<\/h3>\n<ol>\n<li><strong>Take with or after food.<\/strong> This is the single biggest factor in GI tolerability. Empty-stomach dosing causes nausea, dyspepsia and abdominal pain in most patients.<\/li>\n<li><strong>\u039a\u03b1\u03c4\u03b1\u03c0\u03b9\u03b5\u03af\u03c4\u03b5 \u03bf\u03bb\u03cc\u03ba\u03bb\u03b7\u03c1\u03bf \u03bc\u03b5 \u03bd\u03b5\u03c1\u03cc.<\/strong> Do NOT crush, split, or chew controlled-release tablets &mdash; this destroys the controlled-release mechanism and causes a dose dump that produces severe peak-related side effects (drowsiness, tremor, GI upset).<\/li>\n<li><strong>Twice daily for most adults<\/strong>, ideally morning + evening 12 hours apart. Once-daily dosing (full daily dose at bedtime) is reasonable for migraine prophylaxis at 500&ndash;1,000 mg\/day.<\/li>\n<li><strong>Be consistent with timing.<\/strong> Missed doses produce noticeable trough levels. If a dose is missed and remembered within 6 hours, take it. If &gt;6 hours, skip and resume normally &mdash; do not double-dose.<\/li>\n<li><strong>\u03a0\u03c1\u03cc\u03b3\u03c1\u03b1\u03bc\u03bc\u03b1 \u03c0\u03b1\u03c1\u03b1\u03ba\u03bf\u03bb\u03bf\u03cd\u03b8\u03b7\u03c3\u03b7\u03c2:<\/strong> baseline LFTs (AST, ALT, GGT), full blood count, and platelet count <strong>before starting<\/strong>. Repeat at <strong>1 month<\/strong>, <strong>3 \u03bc\u03ae\u03bd\u03b5\u03c2<\/strong>, <strong>6 \u03bc\u03ae\u03bd\u03b5\u03c2<\/strong>, then annually. Check ammonia level if patient develops drowsiness, confusion or vomiting.<\/li>\n<li><strong>Therapeutic drug monitoring:<\/strong> serum valproate trough level is useful in epilepsy (target 50&ndash;100 &micro;g\/mL) and bipolar (target 50&ndash;125 &micro;g\/mL). Not routinely needed for migraine prophylaxis.<\/li>\n<li><strong>\u039c\u03b7\u03bd \u03b4\u03b9\u03b1\u03ba\u03cc\u03c8\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc\u03c4\u03bf\u03bc\u03b1.<\/strong> Sudden discontinuation in epilepsy can precipitate <strong>status epilepticus<\/strong> (medical emergency) even in patients who have been seizure-free for years. Taper over 2&ndash;6 weeks under medical supervision when discontinuing.<\/li>\n<li><strong>Pregnancy prevention<\/strong> (women of childbearing potential): use reliable contraception throughout treatment. Discuss alternative drugs if pregnancy is a possibility &mdash; valproate is one of the most teratogenic drugs in routine clinical use.<\/li>\n<\/ol>\n<h2 class=\"wp-block-heading\">Side Effects of Valprol-CR<\/h2>\n<p><strong>Common (often dose-related, may settle with slower titration):<\/strong><\/p>\n<ul>\n<li>Nausea, vomiting, dyspepsia, abdominal pain<\/li>\n<li>\u03a5\u03c0\u03bd\u03b7\u03bb\u03af\u03b1, \u03ba\u03cc\u03c0\u03c9\u03c3\u03b7<\/li>\n<li>Tremor (fine, postural &mdash; often dose-dependent)<\/li>\n<li>Weight gain (10&ndash;20% of patients gain &gt;5 kg)<\/li>\n<li>Hair thinning or hair loss (reversible on discontinuation)<\/li>\n<li>Diarrhoea or constipation<\/li>\n<li>Increased appetite<\/li>\n<\/ul>\n<p><strong>\u039b\u03b9\u03b3\u03cc\u03c4\u03b5\u03c1\u03bf \u03c3\u03c5\u03c7\u03bd\u03ac \u03b1\u03bb\u03bb\u03ac \u03c3\u03b7\u03bc\u03b1\u03bd\u03c4\u03b9\u03ba\u03ac:<\/strong><\/p>\n<ul>\n<li>Thrombocytopenia (low platelet count) &mdash; usually mild and dose-related; check FBC every visit<\/li>\n<li>Hyperammonaemic encephalopathy &mdash; drowsiness, confusion, vomiting; can occur with normal LFTs; check ammonia level if suspected<\/li>\n<li>Polycystic ovary syndrome features in women &mdash; hyperandrogenism, menstrual irregularity, weight gain<\/li>\n<li>Increased liver enzymes (often asymptomatic)<\/li>\n<li>Pancreatitis (rare but life-threatening)<\/li>\n<li>Cognitive slowing, memory difficulties<\/li>\n<\/ul>\n<p><strong>Rare but seek medical attention immediately:<\/strong><\/p>\n<ul>\n<li><strong>Acute fulminant hepatic failure<\/strong> &mdash; particularly in children under 2 years on polypharmacy. Stop immediately if jaundice, severe vomiting or new lethargy develops.<\/li>\n<li><strong>\u039f\u03be\u03b5\u03af\u03b1 \u03c0\u03b1\u03b3\u03ba\u03c1\u03b5\u03b1\u03c4\u03af\u03c4\u03b9\u03b4\u03b1<\/strong> &mdash; severe abdominal pain, vomiting<\/li>\n<li><strong>\u0395\u03b3\u03ba\u03b5\u03c6\u03b1\u03bb\u03bf\u03c0\u03ac\u03b8\u03b5\u03b9\u03b1 \u03c5\u03c0\u03b5\u03c1\u03b1\u03bc\u03bc\u03c9\u03bd\u03b9\u03b1\u03c7\u03b1\u03bc\u03af\u03b1\u03c2<\/strong> with normal LFTs &mdash; new confusion, drowsiness, vomiting<\/li>\n<li>Severe skin reactions (Stevens-Johnson syndrome, DRESS)<\/li>\n<li>Bone marrow suppression<\/li>\n<li>Severe bleeding from thrombocytopenia or platelet dysfunction<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">\u03a0\u03c1\u03bf\u03b5\u03b9\u03b4\u03bf\u03c0\u03bf\u03b9\u03ae\u03c3\u03b5\u03b9\u03c2 \u03ba\u03b1\u03b9 \u03a0\u03c1\u03bf\u03c6\u03c5\u03bb\u03ac\u03be\u03b5\u03b9\u03c2 \u2014 \u039a\u03a1\u0399\u03a3\u0399\u039c\u039f<\/h2>\n<ul>\n<li><strong>Pregnancy: ABSOLUTE CONTRAINDICATION for migraine (FDA Category X) and STRONG WARNING for epilepsy (Category D).<\/strong> Sodium valproate is one of the most potent human teratogens in routine clinical use. Risk of major congenital malformations (neural tube defects, craniofacial defects, cardiac defects, limb defects, hypospadias) is approximately <strong>10%<\/strong>, plus a 30&ndash;40% risk of significant neurodevelopmental impairment (lower IQ, autism spectrum disorder) in children exposed in utero. Use only if no other option is effective. Women of childbearing potential need: (1) explicit pregnancy-prevention counselling, (2) reliable contraception throughout treatment, (3) preconception folate supplementation 5 mg\/day if pregnancy is planned, (4) urgent specialist review if pregnancy occurs.<\/li>\n<li><strong>Hepatotoxicity:<\/strong> highest risk in children under 2 years on multiple anti-epileptics (rare in adult monotherapy). Stop immediately for jaundice, severe vomiting, lethargy, or worsening seizures.<\/li>\n<li><strong>Pancreatitis:<\/strong> rare but life-threatening; idiosyncratic, can occur at any time during treatment. Seek emergency care for severe abdominal pain.<\/li>\n<li><strong>Hyperammonaemic encephalopathy:<\/strong> can occur with normal LFTs &mdash; check ammonia level if patient develops drowsiness, confusion or vomiting on valproate.<\/li>\n<li><strong>Mitochondrial disease (POLG mutations):<\/strong> absolute contraindication &mdash; valproate causes acute liver failure in this rare population. Genetic testing is appropriate before starting if there is family history of mitochondrial disease or unexplained liver disease.<\/li>\n<li><strong>Urea cycle disorders:<\/strong> contraindication &mdash; valproate precipitates hyperammonaemic encephalopathy.<\/li>\n<li><strong>\u039a\u03af\u03bd\u03b4\u03c5\u03bd\u03bf\u03c2 \u03b1\u03b9\u03bc\u03bf\u03c1\u03c1\u03b1\u03b3\u03af\u03b1\u03c2:<\/strong> valproate impairs platelet function and may cause thrombocytopenia. Tell the surgeon and stop 1&ndash;2 weeks before elective surgery if possible.<\/li>\n<li><strong>Dementia patients:<\/strong> off-label use for behavioural agitation is no longer recommended &mdash; observational data show increased mortality.<\/li>\n<li><strong>\u039c\u03b7 \u03b4\u03b9\u03b1\u03ba\u03cc\u03c0\u03c4\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc\u03c4\u03bf\u03bc\u03b1<\/strong> in epilepsy &mdash; can precipitate status epilepticus.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Contraindications &mdash; Who Should NOT Take Valprol-CR<\/h2>\n<ul>\n<li>Pregnancy or planning pregnancy (especially for migraine prophylaxis &mdash; absolute contraindication)<\/li>\n<li>Known hypersensitivity to valproate or any tablet excipient<\/li>\n<li>Severe hepatic impairment or active liver disease<\/li>\n<li>Personal or family history of severe hepatic dysfunction caused by drugs<\/li>\n<li>Mitochondrial disease (especially POLG mutations)<\/li>\n<li>Urea cycle disorders<\/li>\n<li>Acute porphyria<\/li>\n<li>Children under 2 years (especially on polypharmacy &mdash; high hepatotoxicity risk)<\/li>\n<li>Active pancreatitis<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">\u0391\u03bb\u03bb\u03b7\u03bb\u03b5\u03c0\u03b9\u03b4\u03c1\u03ac\u03c3\u03b5\u03b9\u03c2 \u03a6\u03b1\u03c1\u03bc\u03ac\u03ba\u03c9\u03bd<\/h2>\n<table style=\"border-collapse:collapse;width:100%;margin:12px 0;\">\n<thead>\n<tr style=\"background:#2c7cb0;color:#fff;\">\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">\u03a3\u03c5\u03bd\u03b4\u03c5\u03ac\u03b6\u03b5\u03c4\u03b1\u03b9 \u03bc\u03b5<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">\u0391\u03c0\u03bf\u03c4\u03ad\u03bb\u03b5\u03c3\u03bc\u03b1<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">\u03a4\u03b9 \u03bd\u03b1 \u03ba\u03ac\u03bd\u03b5\u03c4\u03b5<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Lamotrigine<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Valproate doubles lamotrigine levels &mdash; markedly increased risk of severe rash and Stevens-Johnson syndrome<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Reduce lamotrigine dose by 50% when combined; very slow titration. Specialist supervision.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Carbapenems (meropenem, ertapenem, imipenem)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Carbapenems dramatically reduce valproate levels &mdash; can precipitate seizures within days<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Avoid combination. Use alternative antibiotic if valproate is essential.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Phenytoin, carbamazepine, phenobarbital (other AEDs)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Bidirectional protein-binding and metabolism interactions &mdash; unpredictable effects on both drugs<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Monitor levels of both; specialist supervision.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Aspirin (high-dose), NSAIDs<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Displace valproate from albumin; increase free fraction and toxicity<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Avoid high-dose aspirin. Monitor for valproate side effects.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Warfarin, anticoagulants<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Increased anticoagulant effect (displacement) and platelet inhibition by valproate<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Monitor INR more frequently. Watch for bleeding.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">\u03a4\u03bf\u03c0\u03b9\u03c1\u03b1\u03bc\u03ac\u03c4\u03b7<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Increased risk of hyperammonaemia and encephalopathy<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Check ammonia level if symptoms develop.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">\u0391\u03bb\u03ba\u03bf\u03cc\u03bb<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Additive CNS depression and hepatotoxicity<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Limit to occasional small amounts; avoid binge drinking.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">\u03a3\u03c5\u03bd\u03b4\u03c5\u03b1\u03c3\u03c4\u03b9\u03ba\u03ac \u03b1\u03bd\u03c4\u03b9\u03c3\u03c5\u03bb\u03bb\u03b7\u03c0\u03c4\u03b9\u03ba\u03ac \u03c7\u03ac\u03c0\u03b9\u03b1<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">No significant interaction (unlike many other AEDs)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">COCs remain effective. Reliable contraception is mandatory because of teratogenicity.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Benzodiazepines<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Additive CNS depression<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Avoid routine combination; use lowest doses if combined.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2 class=\"wp-block-heading\">\u039f\u03b4\u03b7\u03b3\u03af\u03b5\u03c2 \u0391\u03c0\u03bf\u03b8\u03ae\u03ba\u03b5\u03c5\u03c3\u03b7\u03c2<\/h2>\n<ul>\n<li>\u03a6\u03c5\u03bb\u03ac\u03be\u03c4\u03b5 \u03c3\u03b5 \u03b8\u03b5\u03c1\u03bc\u03bf\u03ba\u03c1\u03b1\u03c3\u03af\u03b1 \u03b4\u03c9\u03bc\u03b1\u03c4\u03af\u03bf\u03c5, <strong>15\u201325\u00b0C<\/strong>. Protect from light and moisture.<\/li>\n<li>\u0394\u03b9\u03b1\u03c4\u03b7\u03c1\u03ae\u03c3\u03c4\u03b5 \u03c4\u03b1 \u03b4\u03b9\u03c3\u03ba\u03af\u03b1 \u03c3\u03c4\u03b7\u03bd \u03b1\u03c1\u03c7\u03b9\u03ba\u03ae \u03c4\u03bf\u03c5\u03c2 \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u03bc\u03ad\u03c7\u03c1\u03b9 \u03c4\u03b7 \u03c7\u03c1\u03ae\u03c3\u03b7.<\/li>\n<li>\u039c\u03b7\u03bd \u03b1\u03c0\u03bf\u03b8\u03b7\u03ba\u03b5\u03cd\u03b5\u03c4\u03b5 \u03c3\u03c4\u03bf \u03bc\u03c0\u03ac\u03bd\u03b9\u03bf \u2014 \u03b7 \u03c5\u03b3\u03c1\u03b1\u03c3\u03af\u03b1 \u03bc\u03b5\u03b9\u03ce\u03bd\u03b5\u03b9 \u03c4\u03b7 \u03b4\u03b9\u03ac\u03c1\u03ba\u03b5\u03b9\u03b1 \u03b6\u03c9\u03ae\u03c2.<\/li>\n<li>Keep out of reach of children &mdash; valproate is highly teratogenic and accidental ingestion by a pregnant household member is a serious risk.<\/li>\n<li>\u039c\u03b7\u03bd \u03c7\u03c1\u03b7\u03c3\u03b9\u03bc\u03bf\u03c0\u03bf\u03b9\u03b5\u03af\u03c4\u03b5 \u03bc\u03b5\u03c4\u03ac \u03c4\u03b7\u03bd \u03b7\u03bc\u03b5\u03c1\u03bf\u03bc\u03b7\u03bd\u03af\u03b1 \u03bb\u03ae\u03be\u03b7\u03c2.<\/li>\n<li>\u0395\u03c0\u03b9\u03c3\u03c4\u03c1\u03ad\u03c8\u03c4\u03b5 \u03c4\u03b1 \u03b1\u03c7\u03c1\u03b7\u03c3\u03b9\u03bc\u03bf\u03c0\u03bf\u03af\u03b7\u03c4\u03b1 \u03b4\u03b9\u03c3\u03ba\u03af\u03b1 \u03c3\u03b5 \u03c6\u03b1\u03c1\u03bc\u03b1\u03ba\u03b5\u03af\u03bf \u03b3\u03b9\u03b1 \u03c3\u03c9\u03c3\u03c4\u03ae \u03b1\u03c0\u03cc\u03c1\u03c1\u03b9\u03c8\u03b7.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">\u03a3\u03c7\u03b5\u03c4\u03b9\u03ba\u03ad\u03c2 \u0395\u03bd\u03b1\u03bb\u03bb\u03b1\u03ba\u03c4\u03b9\u03ba\u03ad\u03c2 \u039b\u03cd\u03c3\u03b5\u03b9\u03c2 \u03c3\u03c4\u03bf MedsBase<\/h2>\n<p>Other medications stocked for epilepsy, bipolar disorder and migraine prophylaxis:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/el\/product-category\/neurological-conditions-and-epilepsy\/\">Browse all neurological + epilepsy medications<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/product-category\/mental-health-and-psychiatric-medications\/\">Browse all mental health and psychiatric medications<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/product-category\/anti-migraine\/\">\u03a0\u03b5\u03c1\u03b9\u03b7\u03b3\u03b7\u03b8\u03b5\u03af\u03c4\u03b5 \u03c3\u03b5 \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03b1 \u03ba\u03b1\u03c4\u03ac \u03c4\u03b7\u03c2 \u03b7\u03bc\u03b9\u03ba\u03c1\u03b1\u03bd\u03af\u03b1\u03c2<\/a><\/li>\n<\/ul>\n<h2 id=\"faqs\">\u03a3\u03c5\u03c7\u03bd\u03ad\u03c2 \u0395\u03c1\u03c9\u03c4\u03ae\u03c3\u03b5\u03b9\u03c2<\/h2>\n<h3 class=\"wp-block-heading\">What conditions is Valprol-CR used for?<\/h3>\n<p>Valprol-CR (sodium valproate + valproic acid) is licensed for: <strong>multiple seizure types in epilepsy<\/strong> (generalised tonic-clonic, absence, myoclonic, partial), <strong>acute mania in bipolar I disorder<\/strong>, \u03ba\u03b1\u03b9 <strong>. \u03a5\u03c0\u03ac\u03c1\u03c7\u03bf\u03c5\u03bd \u03b5\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2 \u03b5\u03ba\u03c4\u03cc\u03c2 \u03b5\u03c4\u03b9\u03ba\u03ad\u03c4\u03b1\u03c2 \u03b3\u03b9\u03b1 \u03c7\u03c1\u03ae\u03c3\u03b7 \u03c3\u03b5<\/strong> in adults. It is one of the broadest-spectrum anti-epileptic drugs available. Off-label uses include neuropathic pain and behavioural agitation in some psychiatric conditions, but it is no longer recommended for behavioural agitation in dementia (mortality signal in observational data).<\/p>\n<h3 class=\"wp-block-heading\">Why is Valprol-CR so dangerous in pregnancy?<\/h3>\n<p>Sodium valproate is one of the most teratogenic drugs in routine clinical use. In-utero exposure carries approximately <strong>10% risk of major congenital malformations<\/strong> (neural tube defects, cardiac defects, craniofacial defects, hypospadias, limb defects) plus a <strong>30&ndash;40% risk of significant neurodevelopmental impairment<\/strong> (lower IQ, autism spectrum disorder). For migraine prophylaxis the FDA classifies it as <strong>Pregnancy Category X (absolute contraindication)<\/strong>; for epilepsy Category D (use only if benefit outweighs the substantial fetal risk and no other option is available). Women of childbearing potential need explicit counselling, reliable contraception, and 5 mg\/day folate before any planned pregnancy.<\/p>\n<h3 class=\"wp-block-heading\">Why must I never stop Valprol-CR abruptly?<\/h3>\n<p>In epilepsy, sudden discontinuation can precipitate <strong>status epilepticus<\/strong> &mdash; a medical emergency where seizures do not stop spontaneously, with significant mortality if untreated. This can happen even in patients who have been seizure-free for years. Always taper over 2&ndash;6 weeks under medical supervision when discontinuing. The same caution applies to bipolar maintenance therapy &mdash; abrupt discontinuation can precipitate a manic relapse.<\/p>\n<h3 class=\"wp-block-heading\">What blood tests do I need on Valprol-CR?<\/h3>\n<p><strong>Before starting:<\/strong> liver function tests (AST, ALT, GGT), full blood count including platelet count, baseline weight, fasting glucose. <strong>\u039a\u03b1\u03c4\u03ac \u03c4\u03b7 \u03b4\u03b9\u03ac\u03c1\u03ba\u03b5\u03b9\u03b1 \u03c4\u03b7\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2:<\/strong> repeat LFTs and FBC at 1 month, 3 months, 6 months, then annually. <strong>If unwell:<\/strong> check ammonia level if any new drowsiness, confusion or vomiting (hyperammonaemic encephalopathy can occur with normal LFTs). For epilepsy, periodic serum valproate trough level (target 50&ndash;100 &micro;g\/mL).<\/p>\n<h3 class=\"wp-block-heading\">Why can I not crush or split Valprol-CR tablets?<\/h3>\n<p>The CR (controlled-release) coating is what produces the sustained 12&ndash;24 hour drug release. Crushing or splitting destroys the coating and causes a &#8220;dose dump&#8221; &mdash; the entire dose is absorbed within 2&ndash;3 hours, producing very high peak levels with severe drowsiness, tremor, GI upset and sometimes hyperammonaemic encephalopathy. If a smaller dose is needed, use immediate-release valproate or step down to the 200 mg CR strength rather than splitting a 750 mg CR tablet.<\/p>\n<h3 class=\"wp-block-heading\">Will Valprol-CR cause weight gain or hair loss?<\/h3>\n<p>Both are common. <strong>\u0391\u03cd\u03be\u03b7\u03c3\u03b7 \u03b2\u03ac\u03c1\u03bf\u03c5\u03c2<\/strong> affects 10&ndash;20% of patients (usually 5&ndash;10 kg over the first 6&ndash;12 months) and is driven by increased appetite plus metabolic effects. Mitigate with consistent diet and exercise. <strong>Hair thinning or hair loss<\/strong> affects up to 10% of patients, usually starts in the first 3&ndash;6 months, and is reversible on dose reduction or discontinuation. Zinc and selenium supplementation is sometimes used (limited evidence).<\/p>\n<h3 class=\"wp-block-heading\">Can Valprol-CR be used with lamotrigine?<\/h3>\n<p>Yes but with extreme caution. Valproate <strong>doubles lamotrigine levels<\/strong> by inhibiting its metabolism, sharply increasing the risk of severe rash and Stevens-Johnson syndrome &mdash; the most serious lamotrigine side effect. The combination is sometimes used (it has good cognitive and seizure-control properties) but lamotrigine must be started at <strong>half the usual dose<\/strong> with a much slower up-titration (12-week protocol). Specialist supervision is essential.<\/p>\n<h3 class=\"wp-block-heading\">Why do certain antibiotics (carbapenems) interact so dangerously with Valprol-CR?<\/h3>\n<p>Carbapenem antibiotics (meropenem, ertapenem, imipenem) <strong>dramatically reduce valproate levels<\/strong> &mdash; sometimes by &gt;90% within 1&ndash;3 days &mdash; through a poorly understood mechanism that may involve enterohepatic recirculation. The result is sudden loss of seizure control even in patients on stable therapeutic levels for years. <strong>Avoid this combination.<\/strong> If a patient on valproate needs a carbapenem (e.g. for hospital-acquired infection), switch the antibiotic to an alternative, OR switch the anti-epileptic before the carbapenem is started.<\/p>\n<h3 class=\"wp-block-heading\">Is Valprol-CR appropriate for behavioural agitation in dementia?<\/h3>\n<p><strong>No longer recommended.<\/strong> Off-label use of valproate for behavioural agitation in Alzheimer&#39;s and other dementias was common until observational studies suggested an <strong>increased mortality signal<\/strong>, similar to the signal that led to black-box warnings on antipsychotic use in dementia. Current guidelines favour non-pharmacological approaches first, then short-term low-dose risperidone or quetiapine if needed, with valproate reserved for very specific cases under specialist supervision.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">\u03a3\u03c7\u03b5\u03c4\u03b9\u03ba\u03ad\u03c2 \u0395\u03bd\u03b1\u03bb\u03bb\u03b1\u03ba\u03c4\u03b9\u03ba\u03ad\u03c2<\/h3>\n<p>\u0386\u03bb\u03bb\u03b1 \u03c0\u03c1\u03bf\u03ca\u03cc\u03bd\u03c4\u03b1 \u03c3\u03b5 <strong>\u03a7\u03c1\u03cc\u03bd\u03b9\u03b5\u03c2 \u03a0\u03b1\u03b8\u03ae\u03c3\u03b5\u03b9\u03c2<\/strong> \u03c0\u03bf\u03c5 \u03bf\u03b9 \u03c0\u03b5\u03bb\u03ac\u03c4\u03b5\u03c2 \u03b5\u03be\u03b5\u03c4\u03ac\u03b6\u03bf\u03c5\u03bd \u03b5\u03c0\u03af\u03c3\u03b7\u03c2:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/el\/gabatop\/\">Gabatop<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/gabimax\/\">Gabimax<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/xepar\/\">Xepar<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/tenof-em\/\">Tenof EM<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/cresar\/\">Cresar<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>Valprol-CR (Sodium valproate CR 200\u2013500 mg) \u2014 anticonvulsant mood stabiliser for epilepsy, bipolar mania, migraine prophylaxis. flatter level curve \u2014 twice-daily controlled-release.<\/p>","protected":false},"featured_media":60657,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3906,3468],"product_tag":[4677,4898,4899],"class_list":{"0":"post-60656","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-mental-health-and-psychiatric-medications","9":"product_cat-neurological-conditions-and-epilepsy","10":"product_tag-sodium-valproate","11":"product_tag-valproic-acid","12":"product_tag-valprol-cr","14":"first","15":"instock","16":"shipping-taxable","17":"purchasable","18":"product-type-variable","19":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product\/60656","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/comments?post=60656"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/media\/60657"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/media?parent=60656"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_brand?post=60656"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_cat?post=60656"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_tag?post=60656"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}